ALNY Alnylam Pharmaceuticals Inc
4,023
$150.19
$0.79
(0.53%)
| Watchers | 4,023 |
| 52-Wk Low | $141.98 |
| 52-Wk High | $218.88 |
| Market Cap | $18.9B |
| Volume | 196,053.00 |
| 52-Wk High | $218.88 |
| 52-Wk Low | $141.98 |
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short InterestBenzinga • 3 days ago
read more...
Share to Feed
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the publication of its 2023 Corporate Responsibility Report. The company continues to take...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2024 and reviewed recent...
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, May...
The latest findings from Alnylam Pharmaceuticals' KARDIA-2 Phase 2 study are on zilebesiran's efficacy and safety in treating hypertension. Results show significant reductions in systolic blood...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from the KARDIA-2 Phase 2 study evaluating the efficacy and safety of a single...
SteelPeak Wealth LLC lowered its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 37.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The...
BMO Capital Markets reissued their outperform rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY - Free Report) in a report published on Wednesday morning, Benzinga reports. The brokerage...